Skip to main content
. 2018 May 25;62(6):e02446-17. doi: 10.1128/AAC.02446-17

TABLE 2.

Magnitudes of avibactam exposures associated with stasis and killing of P. aeruginosa in the neutropenic mouse thigh infection model in the background of q2h dosing of ceftazidimea

Strainb MIC (mg/liter)
Exptf Avibactam %fT>1 mg/literc yielding:
CAZd CAZ-AVIe Stasis 1-log10 kill
1 128 8 Codosing 37.2 65.7
5 128 8 Codosing 14.1 32.9
7 64 4 AVI fractionation 74.1 Not reported
Codosing 50.4 65.3
11 128 16 Codosing 29.1 37.5
18 32 2 AVI fractionation 30.2 Not reported
Codosing 24.2 33.2
19 64 4 Codosing 62.5 67.2
Mean 40.2 50.3
SD 20 17
a

Data were retabulated from Berkhout et al. (44).

b

Resistance summaries for the strains used in this experiment are as follows. Strain 1, nitrocefinase activity, ++; AmpC transcript, overexpressed; β-lactamase genotype, blaAmpC; class A, class B; strain 5: nitrocefinase activity, ++++; AmpC transcript, overexpressed; β-lactamase genotype, blaAmpC; class A, class B; strain 7: nitrocefinase activity, +++; AmpC transcript, overexpressed; β-lactamase genotype, blaAmpC; class A, class B; strain 11: OprD, AmpCcon, class A, class B; strain 18: OprD, AmpCind?, class A, class B; strain 19: OprD, AmpCcon, class A, class B.

c

Times are expressed as the percentages of the dosing interval.

d

CAZ, ceftazidime.

e

AVI, avibactam.

f

Codosing, ceftazidime and avibactam were codosed but the amount of avibactam was varied, without fractionating any given total daily dose; AVI fractionation, avibactam dose fractionation experiments.